

Mouhamed Yazan Abou-Ismaïl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5593709/publications.pdf>

Version: 2024-02-01

20
papers

815
citations

933447

10
h-index

794594

19
g-index

21
all docs

21
docs citations

21
times ranked

1029
citing authors

#	ARTICLE	IF	CITATIONS
1	The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. <i>Thrombosis Research</i> , 2020, 194, 101-115.	1.7	454
2	Central venous catheter-related thrombosis in children and adults. <i>Thrombosis Research</i> , 2020, 187, 103-112.	1.7	91
3	Estrogen and thrombosis: A bench to bedside review. <i>Thrombosis Research</i> , 2020, 192, 40-51.	1.7	87
4	Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT. <i>Blood</i> , 2022, 140, 73-77.	1.4	32
5	Persistence of Ad26.COVS2-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies. <i>American Journal of Hematology</i> , 2022, 97, 519-526.	4.1	26
6	Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: A scoping review of the literature. <i>Haemophilia</i> , 2022, 28, 4-17.	2.1	20
7	Vaccine-induced thrombotic thrombocytopenia following <i>Ad26.COVS2</i> vaccine in a man presenting as acute venous thromboembolism. <i>American Journal of Hematology</i> , 2021, 96, E346-E349.	4.1	19
8	Acquired von Willebrand syndrome in monoclonal gammopathy – A scoping review on hemostatic management. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 356-365.	2.3	18
9	Outgrowing the laboratory diagnosis of type 1 von <i>W</i> illebrand disease: A two decade study. <i>American Journal of Hematology</i> , 2018, 93, 232-237.	4.1	17
10	Thrombotic microangiopathies: An illustrated review. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12708.	2.3	13
11	Left atrial appendage occlusion for management of atrial fibrillation in persons with hemophilia. <i>Thrombosis Research</i> , 2021, 206, 9-13.	1.7	8
12	Short term efficacy of recombinant porcine factor VIII in patients with factor VIII inhibitors. <i>Haemophilia</i> , 2020, 26, 601-606.	2.1	5
13	Outcomes after Treatment with Upfront Cyclophosphamide or Rituximab for Initial Acquired Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , 2019, 134, 1084-1084.	1.4	4
14	Anticoagulation management post-transjugular intrahepatic portosystemic shunt in portal hypertension associated with myeloproliferative neoplasms. <i>Blood Coagulation and Fibrinolysis</i> , 2021, 32, 578-583.	1.0	3
15	How to manage bleeding disorders in aging patients needing surgery. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 529-535.	2.5	2
16	Safety of BNT162b2 mRNA vaccine booster in the setting of Ad26.COVS2-associated VITT. <i>Blood Advances</i> , 2022, 6, 5327-5329.	5.2	2
17	"Outgrowing" the Laboratory Diagnosis of Type 1 Von Willebrand's Disease: A Two Decade Study. <i>Blood</i> , 2016, 128, 871-871.	1.4	1
18	Does recipient body mass index inform donor selection for allogeneic haematopoietic cell transplantation?. <i>British Journal of Haematology</i> , 2022, 197, 326-338.	2.5	1

#	ARTICLE	IF	CITATIONS
19	History of drug use in allogeneic hematopoietic cell transplant recipients. Bone Marrow Transplantation, 2021, 56, 581-585.	2.4	0
20	A Descriptive Analysis of Immune Thrombotic Thrombocytopenic Purpura (iTTP) Patients with Fatal Outcomes in the U.S. Thrombotic Microangiopathy (USTMA) TTP Registry. Blood, 2021, 138, 4227-4227.	1.4	0